Particulate pulmonary delivery systems containing anti-tuberculosis agents

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 30, Issue 4, 2013, Pages 277-291

  Gupta, Anuradha ^a   Pandya, Sanketkumar M ^a   Mohammad, Imran ^a,b   Agrawal, Atul Kumar ^a   Mohan, Mradul ^a   Misra, Amit ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b GlaxoSmithKline Pharmaceuticals Ltd   (India)

Author keywords

Alveolar macrophages; Inhalable; Isoniazid; Lungs; Microparticles; Microspheres; Mycobacterium tuberculosis; Nanoparticles; Respirable; Rifampin

Indexed keywords

CAPREOMYCIN; CORTICOSTEROID; DICHLOROMETHANE; GLYCEROL; LACTOSE; LEUCINE; MACROGOL; MANNITOL; NITROIMIDAZOLE DERIVATIVE; POLOXAMER; POLYVINYL ALCOHOL; RELANZA; RIFAMPICIN; SORBITOL; TIOCARLIDE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; ASPHYXIA; ASTHMA; BIOSAFETY; CONTROLLED RELEASE FORMULATION; DEATH; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG STABILITY; EMULSION; HUMAN; LUNG TUBERCULOSIS; NEBULIZATION; NONHUMAN; PARTICULATE MATTER; PHAGOCYTOSIS; SPRAY DRYING; TOXICOLOGY;

ADMINISTRATION, INHALATION; ANIMALS; ANTITUBERCULAR AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; LUNG; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84877108053     PISSN: 07434863     EISSN: 2162660X     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.2013005684     Document Type: Article

References (55)

1. Hazard Prevention and Control in the Work Environment: Airborne Dust. Geneva: Sustainable Development and Environmental Health Department, WHO 1999 Contract No.: WHO/SDE/OEH/99.14.
2. Rytting E, Nguyen J, Wang X, Kissel T. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin Drug Delivery 2008;5(6):629-39.
3. Misra A, Hickey AJ, Rossi C, Borchard G, Terada H, Makino K, Fourie PB, Colombo P. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis (Edinburgh, Scotland). 2011;91(1):71-81.
4. Terada H, Makino K, Soma G-I, inventors; Remedy 2006 05/18/2006.
5. Verma RK, Singh AK, Mohan M, Agrawal AK, Misra A. Inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulate drug-delivery systems. Ther Delivery. 2011;2(6):753-68.
6. Chan HK, Chew NYK. Novel alternative methods for the delivery of drugs for the treatment of asthma. Adv Drug Delivery Rev. 2003;55(7):793-805.
7. Hira D, Okuda, T., Ichihashi, M., Kojima, H., Okamoto, H. Development of dry salbutamol sulfate powder with high inhalation performance independent of inhalation patterns. Chem Pharm Bull. 2012;60(3):334-40.
8. Muhammad SA, Langrish T, Tang P, Adi H, Chan HK, Kazarian SG, Dehghani F. A novel method for the production of crystalline micronised particles. Int J Pharm. 2010 Mar 30;388(1-2): 114-22.
9. Shekunov BY, York, P. Crystallization processes in pharmaceutical technology and drug delivery design. J Cryst Growth 2000;211(1):122-36.
10. Dhumal RS, Biradar SV, Paradkar AR, York P. Particle engineering using sonocrystallization: salbutamol sulphate for pulmonary delivery. Int J Pharm. 2009 Feb 23;368(1-2):129-37.
11. Panagiotou T, Mesite SV, Fisher RJ. Production of norfloxacin nanosuspensions using microfluidics reaction technology through solvent/antisolvent crystallization. Indust Eng Chem Res. 2009;48(4):1761-71.
12. Mosen K, Backstrom K, Thalberg K, Schaefer T, Kristensen HG, Axelsson A. Particle formation and capture during spray drying of inhalable particles. Pharm Dev Technol. 2004 Nov;9(4):409-17.
13. Amaro MI, Tajber L, Corrigan OI, Healy AM. Optimisation of spray drying process conditions for sugar nanoporous microparticles (NPMPs) intended for inhalation. Int J Pharm. 2011 Dec 12;421(1):99-109.
14. Aquino RP, Prota L, Auriemma G, Santoro A, Mencherini T, Colombo G, Russon P. Dry powder inhalers of gentamicin and leucine: Formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells. Int J Pharm. 2012 Apr 15;426(1-2):100-7.
15. Schoubben A, Blasi P, Giovagnoli S, Ricci M, Rossi C. Simple and scalable method for peptide inhalable powder production. Eur J Pharm Sci. 2010 Jan 31;39(1-3):53-8.
16. Seville PC, Li HY, Learoyd TP. Spray-dried powders for pulmonary drug delivery. Crit Rev Ther Drug Carrier Syst. 2007;24(4):307-60.
17. Taki M, Marriott C, Zeng XM, Martin GP. The production of 'aerodynamically equivalent' drug and excipient inhalable powders using a novel fractionation technique. Eur J Pharm Biopharm. 2011 Feb;77(2):283-96.
18. Ungaro F, d'Angelo I, Coletta C, d'Emmanuele di Villa Bianca R, Sorrentino R, Perfetto B, Tufano MA, Miro A, LaRotonda MI, Quaglia F. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: Modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Controlled Release. 2012 Jan 10;157(1):149-59.
19. Yang ZY, Le Y, Hu TT, Shen Z, Chen JF, Yun J. Production of ultrafine sumatriptan succinate particles for pulmonary delivery. Pharm Res. 2008 Sep;25(9):2012-8.
20. Kwok KK, Groves MJ, Burgess DJ. Production of 5-15 μm diameter alginate-polylysine microcapsules by an air-atomization technique. Pharm Res. 1991;8(3):341-4.
21. Goldenberg MSTO (CA), Beekman, AC. (Thousand Oaks, CA), inventor, Amgen, Inc. (Thousand Oaks, CA), assignee. Sustained-release alginate gels. United States 2003.
22. Cheow WS, Ng ML, Kho K, Hadinoto K. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: Effect of freeze-drying adjuvants. Int J Pharm. 2011 Feb 14;404(1-2):289-300.
23. D'Addio SM, Chan JG, Kwok PC, Prud'homme RK, Chan HK. Constant size, variable density aerosol particles by ultrasonic spray freeze drying. Int J Pharm. 2012 May 10;427(2):185-91.
24. Maa Y-F, Nguyen, P.-A., Sweeney, T., Shire, S.J., Hsu, C. Protein inhalation powders: Spray drying vs spray freeze drying. Pharm Res 1999;16(2):249-54.
25. Relenza (zanamivir) Inhalation Powder. U.S. Food and Drug Administration; 2009 [cited 2012 May 31]; Available from: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ ucm186081.htm.
26. Searles J, Govindan M. Spray drying of biopharmaceuticals and vaccines. In: Jameel F, Hershenson S, Eds. Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals. New York: John Wiley & Sons. 2010:739-60.
27. Roser BJ. Sterile spray drying for stable liquid 21st century pharmaceuticals. Innovations Pharm Technol. 2006(April):50-4.
28. Garcia-Contreras L, Awasthi S, Hickey AJ. Inhaled vaccines for the prevention of tuberculosis. J Mycobact Dis. 2012:1-13.
29. Haikarainen JE (FI), Seppälä K (Helsinki, FI), Munukka J (Espoo, FI), Muttonen E (Espoo, FI), Stares E (Nether Broughton, GB), Murphy M (Letchworth, GB), Young M (Over, GB), inventor Orion Corporation (Espoo, FI), assignee. Inhaler with a dose counter. United States 2004.
30. Hendricks MR, inventor Dry Powder Inhaler. United States 1997.
31. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):600-12.
32. Fiegel J, Garcia-Contreras L, Thomas M, VerBerkmoes J, Elbert K, Hickey A, Edwards D. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm Res. 2008;25(4):805-11.
33. Muttil P, Kaur J, Kumar K, Yadav AB, Sharma R, Misra A. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci. 2007;32(2):140-50.
34. Crowder TM, Hickey AJ, Louey MD, Orr N. A Guide to Pharmaceutical Particulate Science. Boca Raton, FL: Interpharm/CRC. 2003.
35. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005;50(9):1209-27.
36. Steckel H, Markefka P, teWierik H, Kammelar R. Effect of milling and sieving on functionality of dry powder inhalation products. Int J Pharm. 2006 Feb 17;309(1-2):51-9.
37. Lawlor C, O'Sullivan MP, Rice B, Dillon P, Gallagher PJ, O'Leary S, Shoyele S, Keane J, Cryan SA. Therapeutic aerosol bioengineering of targeted, inhalable microparticle formulations to treat Mycobacterium tuberculosis (MTb). J Mater Sci Mater Med. 2012;23(1):89-98.
38. Hirota K, Hasegawa T, Nakajima T, Inagawa H, Kohchi C, Soma G, Makino K, Terada H. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J Controlled Release. 2010;142(3):339-46.
39. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinburgh, Scotland). 2005;85(4):227-34.
40. Bernini E, Chiara M, Garzia R, Brambilla G, Chiesi P, inventors; Process for the preparation of suspensions of drug particles for inhalation delivery. US Patent 6,464,958.2002 Oct 15, 2002.
41. Meenach SA, Kim YJ, Kauffman KJ, Kanthamneni N, Bachelder EM, Ainslie KM. Synthesis, optimization, and characterization of camptothecin-loaded acetalated dextran porous microparticles for pulmonary delivery. Mol Pharm. 2011 2012/02/06; 9(2):290-8.
42. Roush DJ, Lu Y. Advances in primary recovery: Centrifugation and membrane technology. Biotechnol Prog. 2008;24(3):488-95.
43. O' Hara P, Hickey AJ. Respirable PLGA microspheres containing Rifampicin for the treatment of tuberculosis: Manufacture and characterization. Pharm Res. 2000;17(8):955-61.
44. Wang C, Hickey AJ. Isoxyl aerosols for tuberculosis treatment: PREPARATION and characterization of particles. AAPS PharmSciTech. 2010;11(2):538-49.
45. Garcia-Contreras L, Fiegel J, Telko MJ, Elbert K, Hawi A, Thomas M, VerBerkmoes J, Germishuizen WA, Fourie PB, Hickey AJ, Edwards D. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother. 2007;51(8): 2830-6.
46. Garcia-Contreras L, Sung JC, Muttil P, Padilla D, Telko M, VerBerkmoes JL, Elbert KJ, Hickey AJ, Edwards DA. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob Agents Chemother. 2010;54(4):1436-42.
47. Sethi T, Agrawal A. Structure and function of the tuberculous lung: Considerations for inhaled therapies. Tuberculosis (Edinburgh, Scotland). 2010;91(1):67-70.
48. Guideline on the pharmaceutical quality of inhalation and nasal products. London: European Medicines Agency Committeefor Medicinal Products for Human Use (CHMP) 2006. Report No.: EMEA/ CHMP/QWP/49313/2005 Corr Contract No.: EMEA/CHMP/QWP/49313/2005 Corr.
49. Reviewer Guidance for Nebulizers, Metered Dose Inhalers, Spacers and Actuators: US FDA 1993.
50. Mitchell JP, Nagel MW. Particle Size Analysis of Aerosols from Medicinal Inhalers. KONA Powder Part J. 2004(22): 32-63.
51. Hoe S, Traini D, Chan H-K, Young PM. The influence of flow rate on the aerosol deposition profile and electrostatic charge of single and combination metered dose inhalers. Pharm Res. 2009;26(12):2639-46.
52. Hickey AJ, Martonen TB, Yang Y. Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols. Pharm Acta Helv. 1996;71:185-90.
53. Pauluhn J. Overview of testing methods used in inhalation toxicity: From facts to artifacts. Toxicol Lett. 2003;140-141:183-93.
54. Pauluhn J. Overview of inhalation exposure techniques: strengths and weaknesses. Exp Toxicol Pathol. 2005;57 Suppl 1:111-28.
55. Kaur J, Muttil P, Verma RK, Kumar K, Yadav AB, Sharma R, Misra A. A hand-held apparatus for "nose-only" exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages. Eur J Pharm Sci. 2008;34(1):56-65.